President of the Board of Celon Pharma S.A. was a guest of the programme Profit. He answered Agniszka Zaręba’s questions on the company’s results for the first half of 2017, on its presence in international markets and the strategy of global commercialisation of the company’s innovative portfolio. We invite you to view the video.
We encourage you to see the recording and presentation of the Company’s online teleconference held on 25/09/2017 as well as the Q&A session.
A publication dedicated to the company’s financial results in the first half of 2017 and the company’s plans in terms of clinical development of drug candidates. Maciej Wieczorek, PhD: Our generic drugs recorded similar sales rates to last year, which was in line with our expectations. Our financial result in the first half of the year wasRead more »
The Company published its Periodic Report for the 1 half of 2017. The total value of sales generated by the Company in the first half of 2017 amounted to 57 million net, whereas net profit to over 13 million. In terms of volume, the sales of specialised medicinal products which are Polish market leaders inRead more »
Poster Design and development of potent E1 ubiquitin activating enzyme inhibitor, CPL-410-005, as novel anticancer therapy – Presented by the leader of the Oncology research team, Aleksandra Stańczak MD at this year’s largest cancer treatment conference. The European Society of Medical Oncology Meeting was held on 9-12 September. It was participated by 24 thousand participants from 131Read more »
Celon Pharma S.A. received the final decision on the approval of the construction project and granting the Company a building permit for the construction of its Research and Development Centre located in Kazuń Nowy. The total cost of building and equipping the Research and Development Centre with specialised laboratory equipment (without taking into account theRead more »
In line with the contractual provisions, Plexus Ventures will develop a strategy for development of drug candidates and will organise meetings with potential partners. If significant clinical progress is obtained and the parties agree on the development strategy for the drug(s), Plexus Ventures will take steps to obtain partners for the development or licensees, orRead more »
On 26 July this year, the Company submitted an application to build a Research and Development Centre – a modern facility which will integrate i.a. innovative projects of the Company. The total cost of the investment amounts to approx. PLN 80 million. The construction of Research and Development Centre will be financed by the proceedsRead more »
The applications where subject to a full, two-stage expert assessment and were selected from among a total of 23 submitted projects applying for co-funding from the InnoNeuroPharm programme. Maciej Wieczorek, PhD, President of the Board of Celon Pharma S.A.: Sector-specific programmes are very important tools for supporting research and development activity in the entire industry inRead more »